Adoptive Cell Transfer of Allogeneic Epstein–Barr Virus-Specific T Lymphocytes for Treatment of Refractory EBV-Associated Posttransplant Smooth Muscle Tumors: A Case Report
Posttransplant smooth muscle tumors (PTSMTs) are rare Epstein–Barr virus (EBV)-associated neoplasms, mostly occurring after solid organ transplantation. Current therapeutic strategies include surgery and reduction of immunosuppressive medication. We describe for the first time a novel treatment appr...
Guardado en:
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Frontiers Media S.A.
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/97c4af580f24497e83d1ad8348d91f77 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:97c4af580f24497e83d1ad8348d91f77 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:97c4af580f24497e83d1ad8348d91f772021-12-03T04:42:45ZAdoptive Cell Transfer of Allogeneic Epstein–Barr Virus-Specific T Lymphocytes for Treatment of Refractory EBV-Associated Posttransplant Smooth Muscle Tumors: A Case Report1664-322410.3389/fimmu.2021.727814https://doaj.org/article/97c4af580f24497e83d1ad8348d91f772021-12-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fimmu.2021.727814/fullhttps://doaj.org/toc/1664-3224Posttransplant smooth muscle tumors (PTSMTs) are rare Epstein–Barr virus (EBV)-associated neoplasms, mostly occurring after solid organ transplantation. Current therapeutic strategies include surgery and reduction of immunosuppressive medication. We describe for the first time a novel treatment approach for PTSMT by adoptive cell transfer (ACT) of EBV-specific T cells to a 20-year-old patient with a medical history of cardiac transplantation, posttransplant lymphoproliferative disease, and multilocular PTSMT. During ACT, mild cytokine release syndrome occurred, while no unexpected safety signals were recorded. We observed in vivo expansion of EBV-specific T cells and reduction of EBV viremia. Best response was stable disease after 4 months with reduction of EBV viremia and normalization of lactate dehydrogenase levels. ACT with EBV-specific T cells may be a safe and efficacious therapeutic option for PTSMT that warrants further exploration.Bjoern-Thore HansenPetra BacherPetra BacherBritta Eiz-VesperSteffen M. HecklWolfram KlapperKaroline KochBritta Maecker-KolhoffClaudia D. BaldusLars FranseckyFrontiers Media S.A.articleposttransplant smooth muscle tumorsPTSMTsmooth muscle tumoradoptive cell transfervirus-specific T cellsalloCELLImmunologic diseases. AllergyRC581-607ENFrontiers in Immunology, Vol 12 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
posttransplant smooth muscle tumors PTSMT smooth muscle tumor adoptive cell transfer virus-specific T cells alloCELL Immunologic diseases. Allergy RC581-607 |
| spellingShingle |
posttransplant smooth muscle tumors PTSMT smooth muscle tumor adoptive cell transfer virus-specific T cells alloCELL Immunologic diseases. Allergy RC581-607 Bjoern-Thore Hansen Petra Bacher Petra Bacher Britta Eiz-Vesper Steffen M. Heckl Wolfram Klapper Karoline Koch Britta Maecker-Kolhoff Claudia D. Baldus Lars Fransecky Adoptive Cell Transfer of Allogeneic Epstein–Barr Virus-Specific T Lymphocytes for Treatment of Refractory EBV-Associated Posttransplant Smooth Muscle Tumors: A Case Report |
| description |
Posttransplant smooth muscle tumors (PTSMTs) are rare Epstein–Barr virus (EBV)-associated neoplasms, mostly occurring after solid organ transplantation. Current therapeutic strategies include surgery and reduction of immunosuppressive medication. We describe for the first time a novel treatment approach for PTSMT by adoptive cell transfer (ACT) of EBV-specific T cells to a 20-year-old patient with a medical history of cardiac transplantation, posttransplant lymphoproliferative disease, and multilocular PTSMT. During ACT, mild cytokine release syndrome occurred, while no unexpected safety signals were recorded. We observed in vivo expansion of EBV-specific T cells and reduction of EBV viremia. Best response was stable disease after 4 months with reduction of EBV viremia and normalization of lactate dehydrogenase levels. ACT with EBV-specific T cells may be a safe and efficacious therapeutic option for PTSMT that warrants further exploration. |
| format |
article |
| author |
Bjoern-Thore Hansen Petra Bacher Petra Bacher Britta Eiz-Vesper Steffen M. Heckl Wolfram Klapper Karoline Koch Britta Maecker-Kolhoff Claudia D. Baldus Lars Fransecky |
| author_facet |
Bjoern-Thore Hansen Petra Bacher Petra Bacher Britta Eiz-Vesper Steffen M. Heckl Wolfram Klapper Karoline Koch Britta Maecker-Kolhoff Claudia D. Baldus Lars Fransecky |
| author_sort |
Bjoern-Thore Hansen |
| title |
Adoptive Cell Transfer of Allogeneic Epstein–Barr Virus-Specific T Lymphocytes for Treatment of Refractory EBV-Associated Posttransplant Smooth Muscle Tumors: A Case Report |
| title_short |
Adoptive Cell Transfer of Allogeneic Epstein–Barr Virus-Specific T Lymphocytes for Treatment of Refractory EBV-Associated Posttransplant Smooth Muscle Tumors: A Case Report |
| title_full |
Adoptive Cell Transfer of Allogeneic Epstein–Barr Virus-Specific T Lymphocytes for Treatment of Refractory EBV-Associated Posttransplant Smooth Muscle Tumors: A Case Report |
| title_fullStr |
Adoptive Cell Transfer of Allogeneic Epstein–Barr Virus-Specific T Lymphocytes for Treatment of Refractory EBV-Associated Posttransplant Smooth Muscle Tumors: A Case Report |
| title_full_unstemmed |
Adoptive Cell Transfer of Allogeneic Epstein–Barr Virus-Specific T Lymphocytes for Treatment of Refractory EBV-Associated Posttransplant Smooth Muscle Tumors: A Case Report |
| title_sort |
adoptive cell transfer of allogeneic epstein–barr virus-specific t lymphocytes for treatment of refractory ebv-associated posttransplant smooth muscle tumors: a case report |
| publisher |
Frontiers Media S.A. |
| publishDate |
2021 |
| url |
https://doaj.org/article/97c4af580f24497e83d1ad8348d91f77 |
| work_keys_str_mv |
AT bjoernthorehansen adoptivecelltransferofallogeneicepsteinbarrvirusspecifictlymphocytesfortreatmentofrefractoryebvassociatedposttransplantsmoothmuscletumorsacasereport AT petrabacher adoptivecelltransferofallogeneicepsteinbarrvirusspecifictlymphocytesfortreatmentofrefractoryebvassociatedposttransplantsmoothmuscletumorsacasereport AT petrabacher adoptivecelltransferofallogeneicepsteinbarrvirusspecifictlymphocytesfortreatmentofrefractoryebvassociatedposttransplantsmoothmuscletumorsacasereport AT brittaeizvesper adoptivecelltransferofallogeneicepsteinbarrvirusspecifictlymphocytesfortreatmentofrefractoryebvassociatedposttransplantsmoothmuscletumorsacasereport AT steffenmheckl adoptivecelltransferofallogeneicepsteinbarrvirusspecifictlymphocytesfortreatmentofrefractoryebvassociatedposttransplantsmoothmuscletumorsacasereport AT wolframklapper adoptivecelltransferofallogeneicepsteinbarrvirusspecifictlymphocytesfortreatmentofrefractoryebvassociatedposttransplantsmoothmuscletumorsacasereport AT karolinekoch adoptivecelltransferofallogeneicepsteinbarrvirusspecifictlymphocytesfortreatmentofrefractoryebvassociatedposttransplantsmoothmuscletumorsacasereport AT brittamaeckerkolhoff adoptivecelltransferofallogeneicepsteinbarrvirusspecifictlymphocytesfortreatmentofrefractoryebvassociatedposttransplantsmoothmuscletumorsacasereport AT claudiadbaldus adoptivecelltransferofallogeneicepsteinbarrvirusspecifictlymphocytesfortreatmentofrefractoryebvassociatedposttransplantsmoothmuscletumorsacasereport AT larsfransecky adoptivecelltransferofallogeneicepsteinbarrvirusspecifictlymphocytesfortreatmentofrefractoryebvassociatedposttransplantsmoothmuscletumorsacasereport |
| _version_ |
1718373946427965440 |